Age is not a barrier: The older patient with comorbidities
Dr Mary Ann Anderson
Timing is of the essence: The patient with MCL on a BTKi
Dr Martina Pennisi
Charting a course in the CAR T age: SoC in 2L R/R DLBCL
Professor Fabio Ciceri
Optimising patient outcomes in CAR T care
Dr Victoria Campbell
Are we moving towards a cure in R/R lymphoma?
Dr Abdulwahab Albabtain
CAR T in practice: Insights and implications from real-world data
Prof. Roch Houot
Why should CAR T be used earlier in R/R DLBCL?
Dr Claire Roddie
What does the future hold for CAR T manufacturing?
Dr Carl June
CAR T survivorship and summary
Prof. Graham Collins, Dr Mariana Bastos-Oreiro, Dr Pierre Sesques
Choosing CAR T with curative intent
Dr Natasha Kekre
Delivering CAR T
Dr Pierre Sesques
Planning ahead for 2L
Prof. Graham Collins, Dr Mariana Bastos-Oreiro
Diagnosis, treatment and recovery: Perspectives from a patient and a psychotherapist
Ms Surabhi Chaturvedi, Dr Wendy Osborne
How can we bring CAR T’s curative potential to more patients?
Ms Surabhi Chaturvedi, Dr Suzanne van Dorp
What is the most appropriate treatment choice in 2L LBCL? A case-based approach
Dr Wendy Osborne
Why has CAR T become the SoC in 2L LBCL?
Dr Anna Sureda
How can we improve survival outcomes in R/R LBCL?
Dr Cathy Burton
How has CAR T changed survival outcomes in LBCL so far?
Dr Pere Barba, Prof. Peter Vandenberghe
How can we address reimbursement challenges for CAR T?
Adam Hutchings
Why is timely reimbursement of CAR T important for our patients?
Anuradha Rajapakse
Secondary malignancies after Car T-cell therapy
Dr Anna Sureda
Outpatient administration of axi-cel: updates from ZUMA-24 and RWE
Dr Lori Leslie
ALYCANTE: HRQOL post-CAR T in transplant-ineligible patients
Dr Pierre Sesques
CAR-Tography: getting a better understanding of acute toxicities post-CAR T
Dr Kai Rejeski
Can interim PET aid early identification of patients for CAR T?
Prof. Ran Reshef
What approaches are being used to prevent and mitigate CAR T toxicities?
Dr Marcela Maus
How is MCL managed with CAR T? Results from the EBMT survey
Dr Gloria Iacoboni
DESCART registry data in 2L DLBCL (vidéo en français)
Dr Gabriel Brisou
ASTCT Clinical Practice Guidelines for DLBCL
Dr Olalekan Oluwole
Outpatient management in CAR T-cell therapy
Dr Olalekan Oluwole
Updates on ZUMA-1, ZUMA-7 and RWE on the use of CAR T in DLBCL
Dr Jason Westin
Sequencing of bispecific antibodies and CAR T cell therapy
Dr Matthew Frigault
If they RECUR, refer – the importance of early patient identification
Dr Michael Bishop
Real-world evidence on the use of CAR T in R/R adult ALL
Dr Lori Muffly
Centre qualification process
Prof. Graham Collins
Referral considerations
Prof. Graham Collins
RTC and QTC collaborations
Prof. Graham Collins
RTC and QTC relationships
Prof. Graham Collins
Preparing the patient for CAR T